TABLE 1.
Stable IPF | Acute exacerbation of IPF | p-value | |
---|---|---|---|
Subjects n | 30 | 24 | |
Age yrs | 65 ± 8 | 64 ± 9 | 0.91 |
Male | 77% (23) | 79% (19) | 0.83 |
Smoking history | |||
Never-smoker | 27% (8) | 21% (5) | 0.62 |
Former smoker | 60% (18) | 71% (17) | 0.41 |
Current smoker | 13% (4) | 8% (2) | 0.56 |
Current alcohol use | 43% (13) | 54% (13) | 0.43 |
Body mass index | 24.5 ± 3.8 | 25.2 ± 4.0 | 0.56 |
Comorbidities | |||
CAD | 3% (1) | 13% (3) | 0.20 |
GERD | 0% (0) | 8% (2) | 0.11 |
OSA | 0% (0) | 0% (0) | |
PH | 7% (2) | 4% (1) | 0.69 |
Medications | |||
Prednisone# | 17% (10) | 63% (15) | <0.01 |
PPI | 0% (0) | 4% (1) | 0.23 |
H2 blockers | 20% (6) | 38% (9) | 0.15 |
Oestrogen | 0% (0) | 4% (1) | 0.26 |
TLC % pred | 78.5 ± 12.0 | NA | |
FVC % pred | 79.6 ± 16.4 | NA | |
DL,CO % predicted | 68.8 ± 17.4 | NA | |
Intubated¶ | 0% (0) | 8% (2) | 0.11 |
Data are presented as % (n) or mean ± sd, unless otherwise stated. IPF: idiopathic pulmonary fibrosis; CAD: coronary artery disease; GERD: gastrooesophageal reflux disease; OSA: obstructive sleep apnoea; PH: pulmonary hypertension; PPI: proton pump inhibitor; H2: histamine 2 receptor; TLC: total lung capacity; % pred: % predicted; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide.
: prednisone use at the time of bronchoalveolar lavage;
: intubated state at the time of bronchoalveolar lavage.